Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.59 |
| ▸ | NMUR1 | Q9HB89 | 7/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL30979611 | 0.98 | NMUR2 (0.58) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL30979614 | 0.98 | OPRM1 (0.58) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL29416537 | 0.98 | OPRM1 (0.58) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL29973256 | 0.97 | NMUR2 (0.58) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL31473044 | 0.95 | NMUR2 (0.58) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL29484754 | 0.95 | OPRM1 (0.58) | NMUR2NMUR1OPRM1OPRD1IL23R | |
| SCHEMBL30728124 | 0.94 | NMUR2 (0.57) | NMUR2NMUR1OPRM1OPRD1IL23R | |
| SCHEMBL8193601 | 0.94 | NMUR2 (0.60) | NMUR2NMUR1OPRM1OPRD1IL23R | |
| SCHEMBL30423827 | 0.92 | NMUR2 (0.57) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL19728630 | 0.92 | NMUR2 (0.53) | NMUR2NMUR1OPRM1OPRD1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622989-A1 | METHOD OF PREPARING VASOPRESSIN | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024112250-A1 | METHOD OF PREPARING VASOPRESSIN | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2024-05-30 | — | — | WO | claimed |
| US-20260053884-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | PH HEALTH LIMITED (IE) | 2026-02-26 | — | — | US | disclosed |
| US-20260041729-A1 | Vasopressin Formulations for Use in Treatment Of Hypotension | PAR PHARMACEUTICAL INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12447190-B1 | Vasopressin premix systems and uses thereof | BAXTER INTERNATIONAL INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4622989-A1 | METHOD OF PREPARING VASOPRESSIN | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-10-01 | — | — | EP | disclosed |
| EP-4615408-A1 | VASOPRESSIN FORMULATION | Hikma Pharmaceuticals USA Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12186362-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | KAGOSHIMA UNIVERSITY (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024112250-A1 | METHOD OF PREPARING VASOPRESSIN | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024100032-A1 | VASOPRESSIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2024-05-16 | — | — | WO | disclosed |
| US-9750785-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9744209-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744239-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9687526-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170157203-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-06-08 | — | — | US | disclosed |
| US-20170157202-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-06-08 | — | — | US | disclosed |
| US-20170035853-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-02-09 | — | — | US | disclosed |
| US-20160220676-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-08-04 | — | — | US | disclosed |
| US-9375478-B1 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2016-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157203-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | NMUR2 983/4885NMUR1 625/4885OPRM1 1079/4885 |
| US-12186362-B2 | Vasopressin formulations for use in treatment of hypotension | AVPR2, AVPR1B, AVPR1A | NMUR2 983/4885NMUR1 625/4885OPRM1 1079/4885 |
| US-20170157202-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | NMUR2 983/4885NMUR1 625/4885OPRM1 1079/4885 |
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | PTMA, PTMS, CDC37 | NMUR2 3155/4885NMUR1 2490/4885OPRM1 4762/4885 |
| US-20260041729-A1 | Vasopressin Formulations for Use in Treatment Of Hypotension | AVPR1B, AVPR2, AVPR1A | NMUR2 2384/4885NMUR1 1769/4885OPRM1 765/4885 |
| US-20170035853-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | NMUR2 983/4885NMUR1 625/4885OPRM1 1079/4885 |
| US-20260053884-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | AVPR1B, AVPR2, VIP | NMUR2 752/4885NMUR1 684/4885OPRM1 304/4885 |
| US-12447190-B1 | Vasopressin premix systems and uses thereof | AVPR2, AVPR1A, AVPR1B | NMUR2 373/4885NMUR1 389/4885OPRM1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.